Kornimate/medical-research-clean huggingface dataset:
engaging diverse underserved communities to bridge the mammography divide

Conditions: Breast Cancer Screening

Summary: breast cancer is the second most common cause of cancer death in the u.s.1 in spite of being preventable, easily detectable, and curable.2-11 breast screening continues to be underutilized by the general population and especially by traditionally underserved minority populations. two of the least screened minority groups are american indians/alaska natives (ai/an) and latinas. american indian/alaska native women have the poorest recorded 5-year cancer survival rates of any ethnic group and the lowest (or near-lowest) screening rates for major cancers.12 furthermore, breast cancer is the number one cause of cancer mortality among latina women.13 while breast cancer screening rates have increased nationally, there has been an increase in the gap in breast cancer screening utilization between individuals from minority versus majority racial/ethnic groups.

if you decide to participate in the program, your participation will last 4 months. you will complete the healthy living kansas-breast health survey by computer. the survey will take about 20 minutes to complete. you will be randomly assigned (like flipping a coin) to one of two groups. the groups will receive different breast health information. after completing the survey, you agree to be contacted by telephone in 4 months to answer questions. you will be asked for your name, home address, and phone number. you will be given information about breast cancer and mammography. you may or may not benefit from the information provided. care will be taken to safeguard the information you provide but under rare circumstances confidentiality breaches may occur.

Eligibility criteria:
inclusion criteria: * latina or ai/an woman residing in one of participating communities * aged ≥40 years of age * not up to date on mammography screening * home address \& access to a working telephone * responded to 120-day post randomization follow-up call exclusion criteria: * receipt of mammogram within past year * acute medical illness, history of breast cancer, 1st * cognitive impairment or inappropriate affect or behavior * another household member enrolled in the study
effect of preemptive epidural analgesia in labor on cytokine production

Conditions: Obstetric Pain

Summary: during labor there is an increased production of inflammatory mediators called cytokines. higher concentration of certain cytokines has been linked to adverse neonatal and maternal outcomes. epidural analgesia is commonly performed after the parturient feels labor pain. we hypothesis that preemptive epidural analgesia (initiated before labor pain begins)can influence the production of cytokines.

the interrelationship between vaginal labor, cytokine production, and epidural analgesia is unknown. vaginal delivery is thought to induce a maternal inflammatory response. though epidural analgesia during labor was found to significantly influence peripartum maternal and newborn interleukin concentrations, these studies did not address at what stage epidural analgesia was performed. preemptive analgesia has been found to be associated with attenuated proinflammatory cytokines, at least in the postoperative period. healthy asa i term parturients (\>37 weeks) being accepted into delivery ward and wanting epidural analgesia will be studied. parturients will be divided into two groups: * group i- those who have painless contractions awaiting augmentation of labor. * group ii- parturients with cervical dilatation and painful labor (vas \>5). parturients in group i will be given epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (vas\<3). parturients in group 2 will be given epidural analgesia as soon as possible. epidural analgesia protocol will be identical for both groups: graduated doses of bupivicaine 0.1% 15cc and 100 mcg fentanyl followed by patient controlled analgesia at a concentration of bupivicaine 0.1% and fentanyl 2 mcg/cc delivered at 10cc per hour with possible boluses of 5 cc every ten minutes. maternal serum will be drawn before epidural insertion and 18-24 hours after delivery. placental blood will be drawn after delivery. these blood sample will be assessed for il-1beta, tnf alpha, il-1ra, il-2, il-6, il-8, il-10, il-18. the patient's chart will be prospectively analyzed for demographic information about parturient and complications and progress of labor.

Eligibility criteria:
inclusion criteria: 1. age\>18 2. singleton pregnancy with no known fetal malformations 3. above or equal to 38 weeks of pregnancy exclusion criteria: 1. systemic medical illnesses 2. chronic medications except for iron and vitamins 3. women developing fever \> 380c 4. women with history of delivery of children with cerebral palsy 5. history of infertility 6. premature contractions

Keywords: epidural analgesia labor cytokines
determination of risk factors and awareness associated with development of neuromuscular scoliosis

Conditions: Neuromuscular Scoliosis; Deformity

Summary: neuromuscular diseases caused by disruption of the normal conduction relationship between nerve system, neuromuscular junction, and muscles cause scoliosis as a secondary deformity. neuromuscular scoliosis progresses due to muscle weakness and characteristic features of disease. the risk of complications associated with increased progression. morbidity and mortality caused by scoliosis in neuromuscular diseases can be reduced by increasing the knowledge and awareness of the caregivers and physiotherapists. in this study, it was aimed to determine the risk of neuromuscular scoliosis and the factors which can cause in children with disabilities. it is also aimed to reveal inferences related to education levels, awareness of caregivers and professionals working in this field to determine cases with a high risk of scoliosis. thus, it is expected to leading future research to develop preventive treatment approaches. for this purpose, 288 children who are diagnosed with the neuromuscular disease between 3-18 years of age, attending rehabilitation center in istanbul and willing to participate in the research permitted by their caregiver will be included in this study. cerebral palsy follow-up program (cpup), parents and professionals awareness questionnaire related to neuromuscular scoliosis which is prepared by researchers, early onset scoliosis 24 questionnaire, scoliosis research society 22 questionnaire to assess qol, demographic and clinical data also will collect for all sample. patients will be examined for musculoskeletal system, scoliosis analysis will be performed radiologically. data obtained to determine the problems, risk factors, and awareness of the caregivers and physiotherapists will be analyzed statistically.


Eligibility criteria:
inclusion criteria: * diagnosed with neuromuscular disease or cerebral palsy * receiving treatment at a rehabilitation center in istanbul * willing to participate in the research and permitted by their caregiver exclusion criteria: * spinal infections, tumors, trauma * trauma history of lower extremity

Keywords: neuromuscular diseases cerebral palsy awareness risk factors
subclinical diabetes confirmed by 75gm-ogtt influence on the prognosis of decompensated cirrhosis

Conditions: Liver Cirrhosis

Summary: disorders of glucose metabolism, such as impaired glucose intolerance (igt) and diabetes mellitus (dm), frequently occur in cirrhosis. however, it has been underestimated when fasting plasma glucose (fpg) levels are considered. we aimed to evaluate who needs to be undertaken a 75-g oral glucose tolerance test (ogtt) to find underlying subclinical diabetes.


Eligibility criteria:
inclusion criteria: * liver cirrhosis * admitted to a hospital exclusion criteria: * previously confirmed dm * being treated for dm * standard risk factors of t2dm, such as high body mass index and family history of diabetes * symptoms of dm, such as increased thirst and the need to urinate * either hepatocellular carcinoma or other malignancy * hepatic failure or uncontrolled decompensation \[that is, refractory ascites or active variceal hemorrhage\] * significant illnesses such as sepsis that may have interfered with glucose metabolism * pancreatic dysfunction such as acute/chronic pancreatitis that may have affected glucose metabolism.
orbital floor fracture repair by titanium mesh via transantral approach.

Conditions: Orbital Fractures

Summary: the aim of the study is to evaluate the feasibility of cad/cam osteosynthesis mesh through a transantral surgical approach in the repair of orbital floor fractures by means of clinical and radiographic findings.

a cad/cam osteosynthesis mesh through a transantral approach should assumingly provide accurate reconstruction of the orbital volume and anatomy while eliminating the usual morbidity of lower eyelid approaches during orbital reconstruction.

Eligibility criteria:
inclusion criteria: * patients with recent unilateral orbital floor fracture indicated for internal reconstruction - * (isolated or in combination with other facial fractures) * with existing or estimated enophthalmos based on radiographs and a contra-lateral healthy non-operated orbit. exclusion criteria: * delayed cases (more than 2 weeks) * previously operated cases * bilateral orbital floor fracture.
nursing and pharmacy care between capecitabine and 5-fluoruracil regimens

Conditions: Gastric Cancer

Summary: the objective of this study is to compare the possible time savings from reduction of nursing and pharmacy time to manage aegc patients using capecitabine-based regimens versus traditional intravenous chemotherapy in the hong kong public hospital setting.

advanced esophageal and gastric cancer (aegc) have ranked in the top 10 cancer-related cause of death worldwide, with approximately one million new cases each year. over half of new cases are in east asia. the traditional chemotherapy for aegc remains on intravenous (iv) fluorouracil (5-fu), cisplatin, and the anthracyclines. trials favoured the combined use of 5-fu and cisplatin for superior efficacy and quality of life in aegc patients. recent years, oral chemotherapy has a more practical and economic advantages over iv regimen. it is understandable that patients prefer oral regimens as long as the clinical efficacy is maintained. oral treatment strategy preserves quality of life for aegc patients. in addition, it may also have additional cost saving in the nursing and pharmacy time. it is because a significant amount of time can be saved in both nursing and pharmacy for the preparation and administration of iv chemotherapy however, there is a lack of local data to demonstrate the impact of pharmacy and nursing care utilizing capecitabine-based regimen comparing to traditional iv chemotherapy in mcrc patients of hong kong.

Eligibility criteria:
inclusion criteria: 1. aged 18 or above 2. diagnosed with aegc and were prescribed with either xelox-based or folfox4- based chemotherapy treatment exclusion criteria: 1. persons \< 18 years of age; 2. pregnant or lactating women; 3. persons related unequally to investigators (e.g. student, employee); 4. special population (e.g. prisoner, mentally, congnitively disabled); 5. patients who refused to sign consent or not willing to participate.
renal denervation in refractory hypertension

Conditions: Hypertension; Resistant to Conventional Therapy

Summary: open, multicenter, randomized study is enrolling patients in 3 sites in czech republic. patients with refractory hypertension will be randomized in 1:1 manner either to renal denervation plus optimal medical antihypertensive treatment without spironolactone or to antihypertensive treatment alone including spironolactone if not contraindicated. the primary end-point is change in systolic and diastolic blood pressure (bp) between baseline and 1 year after randomization evaluated by 24-hours bp monitoring. expected enrollment is 120 patients. patients follow-up is planned for 3 years.


Eligibility criteria:
inclusion criteria: * refractory hypertension with office sbp \> 140 mmhg * sbp \> 130 during 24-hours holter blood pressure monitoring * treatment with the least 3 antihypertensive medications including diuretics in optimal doses * age \> 18 years * signed informed consent exclusion criteria: * secondary forms of hypertension * chronic renal disease (serum creatinine \> 200 umol/l) * pregnancy * history of myocardial infarction or stroke in last 6 months * severe valvular stenotic disease * anatomic abnormalities and variants of renal artery including aneurysms, severe stenosis, reference diameter \< 4 mm or length \< 20 mm * increased bleeding risk (thrombocytopenia \ 1.5)

Keywords: renal denervation resistant hypertension spironolactone long-term outcome
patients with severe eosinophilic asthma treated with benralizumab

Conditions: Asthma; Eosinophilic

Summary: retrospective, multicenter, routine clinical practice study with consecutive inclusion of adult patients with severe eosinophilic asthma receiving benralizumab treatment.

retrospective study studying severe eosinophilic asthma. patients with this disease who are on benralizumab treatment for at least 4 months before the start of the study will be included. the purpose of this study is to analyze the predictive factors of response in patients with this type of disease treated with benralizumab, who obtain a complete response during their follow-up. the results of the study will be obtained through the review of medical records, where demographic characteristics such as age, gender and smoking will be assessed; presence of comorbidities; clinical-functional variables; response variables (exercises, cycles of oral corticosteroids, admissions, visits to the emergency room or unscheduled, cumulative dose of oral corticosteroids, absenteeism from work) and side effects.

Eligibility criteria:
inclusion criteria: * adult patients (over 18 years of age) diagnosed with severe eosinophilic asthma on benralizumab treatment for at least 4 months from the start of the study. exclusion criteria: * patients for whom no previous history is available or who do not meet the inclusion criteria.
an observational follow-up study of 1st-line treatment with herceptin (trastuzumab) in patients with metastatic breast cancer (post-hermine)

Conditions: Breast Cancer

Summary: this is an observational follow-up study on the efficacy of 1st-line treatment with herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.


Eligibility criteria:
inclusion criteria: * female patient, \>/= 18 years of age * metastatic breast cancer * 1st-line treatment with herceptin initiated in 2002 * included in pharmaco-epidemiologic hermine study exclusion criteria: * patient died before scheduled follow-up visit (march 2005)
working toward wellness

Conditions: Depression

Summary: working toward wellness is a telephone care management and outreach monitoring program designed to help medicaid recipients who are experiencing major depression to enter and remain in evidence-based treatment. to study the effects of working toward wellness, individuals receiving medicaid in rhode island who are eligible for mental health services through united behavioral health were screened by telephone for depression. those who were found to have major depression and who agreed to be in the study were randomly assigned. program participants received intensive monitoring from master's level clinicians called care managers to facilitate and support clinical treatment. the control group received usual care that included only referrals to mental health treatment providers. the study hypothesis is that telephonic care management would increase visits to mental health professionals and use of appropriate medication, which in turn would reduce depression severity and lead to greater employment and productivity at work.


Eligibility criteria:
inclusion criteria: * score of 5 or higher on quick inventory of depression symptomatology * receiving medicaid * at least one child in household exclusion criteria: * bipolar disorder * alcohol or substance abuse * currently in active treatment for depression * receiving supplemental security income

Keywords: telephonic care management
haemocomplettan® p during elective complex cardiac surgery

Conditions: Fibrinogen Deficiency in Complex Cardiac Surgery

Summary: fibrinogen concentrate is increasingly used in cardiac surgery to reverse coagulopathy. whether its use reduces blood loss, transfusion and occurrence of clinical adverse events remains unknown.

fibrinogen concentrate is increasingly used in surgical patients suffering excessive bleeding refractory to conventional hemostasis treatment. however, these studies published so far comprise small study groups with questionable study designs. the aim of this study is to determine whether fibrinogen concentrate reduces blood loss and transfusion in patients undergoing elective complex cardiac surgery. by choosing the domain of complex cardiac surgery which is prone for excessive blood loss and transfusion, we will focus on subjects undergoing high risk procedures. hereby we hypothesize that administration of fibrinogen concentrate improves hemostasis in patients experiencing microvascular bleeding during complex cardiac surgery. this improvement of the hemostasis is measured by reduced blood loss and transfusion of blood products during surgery and the postoperative period. furthermore, we hypothesize that fibrinogen concentrate is safe and well tolerated in patients undergoing complex cardiac surgery. this hypothesis will be investigated by a detailed study of clinical outcomes. update regarding interim-analysis: on 09 august 2013 an interim-analysis was performed as described in the protocol. the outcome was discussed during the steering committe of 09 october 2013. during that meeting, based on the results of the interim-analysis, the continuation of the current study was ordered.

Eligibility criteria:
inclusion criteria: * eighteen years of age or older. * undergoing elective complex cardiac surgery. * understood and willingly given written informed consent. * experience clinically relevant non-surgical microvascular bleeding following removal of cardiopulmonary bypass. exclusion criteria: * positive pregnancy test, pregnancy or lactation. * undergoing an emergency operation. * proof or suspicion of a congenital or acquired coagulation disorder. * clopidogrel use in the 5 days preceding surgery. * inr \>1.4 if on coumadin.

Keywords: fibrinogen concentrate coagulopathy
microdissection testicular sperm extraction (microtese) and ivf-icsi outcome in non-obstructive azoospermia (noa)

Conditions: Azoospermia; Infertility

Summary: we evaluated the application of surgical testicular exploration with the aid of a microscope (mictotese) to increase the chances of obtaining sperm in men with impaired sperm production, a condition known as non-obstructive azoospermia. we also evaluated the outcomes of these couples when the sperm obtained were used in icsi (intracytoplasmic sperm injection) during assisted reproductive technology treatment. we believe that excellent results may be obtained with the use of the following techniques in the treatment of couples where non-obstructive azoospermia is a significant cause.

men diagnosed with non-obstructive azoospermia and seeking assisted reproductive technology treatment (art) are candidates for surgical sperm retrieval with the aid of microdissection. we believe that this approach may currently be the best option for these subjects. we evaluated our surgical sperm retrieval rate associated to their serum lh, fsh, total testoterone and prolactin levels, pre-operative testicular volume and also compared to the post-operative histological analysis of fixed testicular tissue specimens collected during the procedure, stained with haematoxylin and eosin. we also evaluated the outcomes using icsi based art for these couples observing mean icsi and fertilized oocytes, number and quality of embryos transferred, implantation and pregnancy rates.

Eligibility criteria:
inclusion criteria: * men undergoing art treatment with clinical diagnosis of non-obstructive azoospermia. * female partner undergoing icsi based art treatment exclusion criteria: * men where non-obstructive azoospermia was not confirmed based on histological analysis of fixed testicular tissue specimens collected by open surgical testicular biopsy and stained with haematoxylin and eosin.

Keywords: tese non-obstructive microdissection azoospermia icsi
testing two interventions to improve health outcomes and quality of life among rural older adults living with hiv

Conditions: HIV

Summary: engagement in hiv medical care and adherence to hiv medications are both essential in improving health outcomes among people living with hiv (plh), but plh living in rural areas-who suffer higher mortality rates than their urban counterparts-can confront multiple barriers to care engagement and adherence, especially as they face the logistical, medical, and social challenges associated with aging. this project will test the efficacy of two interventions to determine their impact on hiv health outcomes and quality of life among rural, older plh living in the southern u.s. the two interventions, adapted from evidence-based interventions and delivered remotely, are: (1) supportive-expressive peer social support groups and (2) strengths-based case management. we hypothesize that both interventions will increase viral suppression, antiretroviral therapy adherence, and health-related quality of life and decrease depressive symptoms. results from this study will provide us with tools to improve health outcomes for rural older people living with hiv.


Eligibility criteria:
inclusion criteria: * aged 50 years or greater * living in a county with a score of .4 or higher on the index of relative rurality (irr) * living in alabama, arkansas, delaware, florida, georgia, kentucky, louisiana, maryland, mississippi, missouri, north carolina, oklahoma, south carolina, tennessee, texas, virginia, or west virginia * living with hiv * has a telephone at home * able to provide informed consent exclusion criteria: * not meeting eligibility criteria described above